Barclays analyst Gena Wang raised the firm’s price target on Ionis Pharmaceuticals to $45 from $37 and keeps an Equal Weight rating on the shares. In Q3, Ionis reported a modest beat in Spinraza royalty and Tegsedi/Waylivra revenues, the firm pointed out in a research note on Friday. Management reiterated 2023 revenue guidance and highlighted several pipeline catalysts achieved. Qalsody CHMP in EU and eplontersen PDUFA both remained on track for Q4 2023, Barclays added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmaceuticals reports Q3 EPS ($1.03), consensus ($1.07)
- Ionis reports third quarter 2023 financial results
- Ionis Pharmaceuticals Inc. (IONS) Q3 Earnings Cheat Sheet
- Biogen says Phase 1b data on BIIB080 in Alzheimer’s showed ‘favorable trends’
- Ionis Pharmaceuticals upgraded to Neutral from Underperform at BofA
